Using the 264 proxy statements, we have gathered data on the compensation of executives responsible for business and/or corporate development in the industry. The sample size of companies shrinks to 72 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Aastrom Biosciences Inc.** Brian S. Hampson 195 0 195 0 36 231 36 243 Alkermes Inc.* Michael J. Landine 289 105 394 6 0 400 799 335 Allos Therapeutics Inc. Eric D. Malek 210 55 265 2 0 267 77 0 Alnylam Pharmaceuticals Inc

For The 64 Business And Corporate Officers In BioWorld's 269-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 David L. Brinkley Theravance Inc. 301 1,182 1,483 2 Ian T. Clark Genentech Inc. 350 555 905 3 Oliver S. Fetzer Cubist Pharmaceuticals Inc. 364 150 514 4 John A. Keller Incyte Corp. 311 200 511 5 Dominick Colangelo Oscient Pharmaceuticals Corp. 293 215 508 6 William J

Using the 269 proxy statements, we have gathered data on the compensation of executives responsible for Research & Development (R&D) in the industry. The sample size of companies shrinks to 164 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no such

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Acadia Pharmaceuticals Inc. Mark R. Brann 295 55 350 0 0 350 210 2,334 Accelrys Inc.^^ Nicholas Austin 225 30 255 0 0 255 0 82 Access Pharmaceuticals Inc. David P. Nowotnik 251 25 276 7 0 283 58 0 Acusphere Inc. Howard

For The 164 R&D Executives In BioWorld's 269-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Roger M. Perlmutter Amgen Inc. 846 1,500 2,346 2 Norbert W. Bischofberger Gilead Sciences Inc. 577 494 1,070 3 James F. Young MedImmune Inc. 571 480 1,051 4 Richard H. Scheller Genentech Inc. 451 529 980 5 George D. Yancopoulos Regeneron Pharmaceuticals 521 280 801 6 Claude D

Using the 269 proxy statements, we have gathered data on the compensation of Chief Financial Officers (CFOs) in the industry. The sample size of companies shrinks to 210 in the case of CFOs because many companies have no CFO listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number of companies have no such position at all. The CFO listed for all

Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Aastrom Biosciences Inc.** Alan M. Wright (1) 206 0 206 0 0 206 45 306 Acadia Pharmaceuticals Inc. Thomas H. Aasen 255 51 306 0 0 306 0 1,318 Accelrys Inc.^^ David M. Sankaran (2) 225 30 255 103 0 358 136 40 Accentia

For The 210 CFOs In BioWorld's 269-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Richard D. Nanula Amgen Inc. 766 1,210 1,976 2 Dennis L. Winger Applera Corp./Celera Genomics^ 543 625 1,168 3 Krish S. Krishnan New River Pharma Inc. 359 675 1,034 4 Robert J. Hugin Celgene Corp. 561 421 981 5 John F. Milligan Gilead Sciences Inc. 496 426 921 6 David F. Hoffmeister

Rank Name of Executive Age Company FYE Value of Exercisable In-the-Money Options ($000) Total No. of Shares Owned By CEO # Percent of Co. Stock Owned By CEO ## (%) Stock Price 12/31/04 Stock Price 12/31/05 ($) Percent Change Stock Price (%) 1 Arthur D. Levinson 55 Genentech Inc. 251,742 NA NA 54.44 92.5 41.1 2 John C. Martin 54 Gilead Sciences Inc. 147,848 4,460,327 NA 34.99 52.57 33.4 3 John W. Jackson 61 Celgene Corp. 108,262 6,305,064 1.8 26.52 64.8 59.1

Rank Name of Executive Company Potential Realizable Value of Option Grants # ($000) No. of Securities Under-Lying Options ($000) % of Total Options Granted To Employees (%) Exercise or Base Price ($/Share)## Stock Price 12/31/04 ($) 1 Martine A. Rothblatt United Therapeutics Corp. 30,251 1,169 45.57 56.36 69.12 2 John W. Jackson (1) Celgene Corp. 23,065 1,798 9.10 24.13 64.8 3 Henri A. Termeer Genzyme Corp. 16,833 425 5.32 62.98 70.78 4 James C. Mullen Biogen

The data presented in these tables were obtained from proxy statements and annual reports of 264 biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 31, 2005. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The CEO listed for 244 companies is the individual who held that title for the majority of the fiscal year reported. In

Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FTE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Stock Price 12/31/04 ($) Stock Price 12/31/05 ($) Percent Change Stock Price (%) Shares Out ($M) Approx. Long-Term Mkt. Cap. 12/31

CEOs Whose Total Direct Compensation Exceeded $1 Million Name of Executive Company Base Salary ($000) Bonus ($000) Other ($000) Long-Term Compensation ($000) Total Direct Compensation ($000) Arthur D. Levinson Genentech Inc. 976 2,000 252 66,268 69,495 John W. Jackson (1) Celgene Corp. 801 1,001 211 41,962 43,974 Henri A. Termeer Genzyme Corp. 1,365 1,760 32 33,224 36,381 Kevin W. Sharer Amgen Inc. 1,390 4,500 732 27,865 34,487 John C. Martin Gilead Sciences

Rank Name of Executive Company Bonus ($000) Base Salary ($000) Bonus As a Percent of Base Salary (%) Other ($000) Stock Price 12/31/04 ($) Stock Price 12/31/05 ($) Percent Change Stock Price (%) 1 Kevin W. Sharer Amgen Inc. 4,500 1,390 323.7 732 64.15 78.86 18.7 2 Arthur D. Levinson Genentech Inc. 2,000 976 205.0 252 54.44 92.5 41.1 3 Tony L. White Applera/Celera Genomics 1,798 1,000 179.8 295 13.75 10.96 -25.5 4 Henri A. Termeer Genzyme Corp. 1,760 1

Rank Name of Executive Company Base Salary ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Stock Price 12/31/04 ($) Stock Price 12/31/05 ($) Percent Change Stock Price (%) Approx. Mkt. Cap. 12/31/05 ($M) 1 Kevin W. Sharer Amgen Inc. 1,390 1,302 6.4 64.15 78.86 18.7 96,524.6 2 Henri A. Termeer Genzyme Corp. 1,365 1,300 4.8 58.07 70.78 18.0 558.2 3 Frank Baldino Jr. Cephalon Inc. 1,065 968 9.1 50.88 64.74 21.4 375.4 4 Tony L. White

For The 244 CEOs In BioWorld's 269-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) Stock Price 12/31/05 Shares Out (M) Approx. Mkt. Cap. 12/31/05 ($M) 1 Kevin W. Sharer Amgen Inc. 1,390 4,500 5,890 78.86 1,224.0 96,524.6 2 Henri A. Termeer Genzyme Corp. 1,365 1,760 3,125 70.78 259.3 18,350.3 3 Arthur D. Levinson Genentech Inc. 976 2,000 2,976 92.50 1053.7 97,468.5 4 Tony L

For Legal Executives Who Received A Full Year Of Salary, 84 Companies